Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.[1] Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi.[2][3]
Nicox is listed on Euronext Paris[4] (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three programs in development, and it has two U.S. Food and Drug Administration (FDA) approved products.[5]
Pipeline
Nicox's lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure (IOP) in patients with glaucoma.